Assertio Holdings, Inc. Common Stock (ASRT)
Assertio Holdings, Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for neurological and other specialized conditions. It provides products that address unmet medical needs, often through drug delivery mechanisms aimed at improving patient outcomes. The company operates in the United States and offers a portfolio of medications targeting areas such as pain management, neurology, and inflammation.
Company News
A federal class action lawsuit against Spectrum Pharmaceuticals alleges the company misled investors about its cancer treatment drug poziotinib's success, causing significant stock price decline after FDA concerns were revealed.
Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance. Asana reported quarterly losses of 4 cents per share which beat the analyst consensus estimate of losses of 10 cents by 60%. Quarterly sales came in at $171.1 million, beating the analyst consensus estimate of $167.676 million by 2.04%...
Assertio (ASRT) appears weighed down by the recent leadership transition. The company is also facing challenges with sales of its product franchisee of late.
Assertio Holdings appears to have been oversold based on quantitative factors. Read why I'm issuing a Buy rating for ASRT stock but suggest diversifying.
Penny stocks to watch this week. The post Best Penny Stocks To Buy? 4 Under $1.10 To Watch Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.